

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

TWI PHARMACEUTICALS, INC.,
Petitioner,

v.

MERCK SERONO S.A.,
Patent Owner.

Case IPR2023-00049
Patent 7,713,947

Case IPR2023-00050
Patent 8,377,903

DECLARATION OF ALAIN MUNAFO, Ph.D.

Merck 2053

I, Alain Munafo, Ph.D., declare as follows:

I. INTRODUCTION

1. I am over eighteen years of age, and I am competent to testify as to the matters set forth herein if I am called upon to do so.

2. I submit this Declaration on behalf of Merck Serono S.A. (“Patent Owner”) for consideration by the Patent Trial and Appeal Board in the following *Inter Partes* Review proceedings: IPR2023-00049 (“’049 IPR”) and IPR2023-00050 (“’050 IPR”). I understand that the ’049 IPR corresponds to *Inter Partes* Review of U.S. Patent No. 7,713,947 (“the ’947 patent”) (Ex. 1001) and the ’050 IPR corresponds to *Inter Partes* Review of U.S. Patent No. 8,377,903 (“the ’903 patent”) (Ex. 1002).

3. I am being compensated for my time in preparing this declaration at my usual consulting rate of 450 Swiss Francs per hour. My compensation is in no way contingent on the substance of my testimony or the outcome of this or any other proceeding.

4. I am a named co-inventor of both the ’947 patent and the ’903 patent. When U.S. Provisional Application No. 60/638,669 and European Provisional Application No. EP04106909, to which the ’947 patent and the ’903 patent claim priority, were filed on December 22, 2004, and for more than two years before

then, I was working with other co-inventors of the '947 patent and the '903 patent to design and develop an oral dosing regimen for cladribine.”

5. I am providing this declaration as a co-inventor of the '947 patent and the '903 patent and as someone knowledgeable about the relationship and joint research and development agreement between the teams at Serono¹ and IVAX.²

6. I have reviewed copies of U.S. Pat. No. 7,888,328 (“Bodor '328”) and PCT Application WO 2004/087101 (“Bodor PCT”) which were provided to me by counsel. I understand Bodor '328 is numbered Ex. 1029 in both IPRs and the Bodor PCT is numbered Ex. 1007 in both IPRs. Bodor '328 and the Bodor PCT each name Drs. Bodor and Dandiker as co-inventors.

7. Bodor '328 includes the following disclosure of a regimen for treating multiple sclerosis (MS) using cladribine:

¹ Serono S.A. is a subsidiary of Patent Owner, Merck Serono S.A. I collectively refer to Ares Trading S.A., its parent Serono S.A., and their other affiliates including Serono International S.A. and Serono Inc., between 2002 and 2004, as “Serono” throughout this declaration.

² I understand that IVAX Corporation is an affiliate of IVAX International GmbH. I collectively refer to IVAX Corporation and IVAX International GmbH as “IVAX” throughout this declaration.

At the present time, it is envisioned that, for the treatment of multiple sclerosis, 10 mg of cladribine in the instant complex cladribine-cyclodextrin complex in the instant solid dosage form would be administered once per day for a period of five to seven days in the first month, repeated for another period of five to seven days in the second month, followed by ten months of no treatment.

'049 Ex. 1029, 13:19-25; '050 Ex. 1029, 13:19-25. The Bodor PCT contains the same language. '049 Ex. 1007, 23:15-20; '050 Ex. 1007, 23:15-20.

8. Bodor '328 (and the Bodor PCT) also include a disclosure of an “alternative” regimen for treating multiple sclerosis (MS) using cladribine:

Alternatively the patient would be treated with 10 mg of cladribine in the instant complex cladribine-cyclodextrin complex in the instant dosage form once per day for a period of five to seven days per month for a total of six months, followed by eighteen months of no treatment.

'049 Ex. 1029, 13:25-30; '050 Ex. 1029, 13:25-30; '049 Ex. 1007, 23:20-24; '050 Ex. 1007, 23:20-24.

9. The Bodor PCT also includes a reference to two provisional applications apparently filed by IVAX. '049 Ex. 1007, 23:24-29; '050 Ex. 1007,

23:24-29. I was not aware of these provisional applications. And I do not know their subject matter.

10. In addition to my recollection and my review of Bodor '328 and the Bodor PCT, I reviewed the materials cited herein, which refreshed my memory about some details of what occurred from 2002 to 2004.

II. BACKGROUND

11. I was the former Global Head of Quantitative Pharmacology and then Executive Scientific Director in Translational Medicine at Merck Serono and am currently retired. My whole professional career relates to clinical pharmacology and pharmaceutical experience, including 27 years in the pharmaceutical industry. My work at Serono (including at Merck Serono) focused on clinical pharmacology, pharmacodynamics and pharmacokinetics, and translational aspects thereof. My work supported Merck Serono's drug development from concept phase in discovery through late-stage clinical development programs, including regulatory submissions. I have also lectured on bioanalytics, clinical pharmacology, and drug development science, in particular at the School of Pharmacy, Lausanne University, and Lausanne University Hospital, Switzerland. A copy of my current CV is attached as Appendix A.

12. I received my Pharmacists Diploma from Lausanne University in 1980 and a Ph.D. in Pharmacy from Lausanne University in 1985. I completed a

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.